Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Webcasts|March 22, 2021

Elevating Your Charge Variant and Aggregate Analysis for Biotherapeutic Proteins

Author(s)Agilent

*Monday, March 22, 2021 at 9am EDT| 1pm GMT | 2pm CET, Monday, March 22, 2021 at 2pm EDT| 1pm CDT | 11am PDT* High resolution is one of the key challenges in modern biopharmaceutical analysis. In this webinar learn the importance of considering the entire liquid chromatography (LC) system to gain optimum results and maximum resolution from your LC column. *On demand available after final airing until March 22, 2022*

Register Free: ​ https://www.biopharminternational.com/bp_w/elevating

Event Overview:

High resolution is one of the key challenges in modern biopharmaceutical analysis. In this webinar learn the importance of considering the entire liquid chromatography (LC) system to gain optimum results and maximum resolution from your LC column.

Modern biopharmaceuticals, such as monoclonal antibodies, are highly heterogeneous compounds. Two of the most important critical quality attributes, charge variants and aggregate analysis, require accurate and reliable results using ion exchange and size exclusion chromatography.

Key Learning Objectives:

  • Impact of extra column dead volume
  • Importance of high-performance pumps
  • Best practices of running high-resolution shallow gradients

Speakers: Dr. Andrew Coffey, Senior Applications Chemist, Agilent Technologies

Dr. Sonja Schneider, Manager Application Development, Agilent Technologies

Times and Dates:

Monday, March 22, 2021 at 9am EDT| 1pm GMT | 2pm CET

Monday, March 22, 2021 at 2pm EDT| 1pm CDT | 11am PDT

On Demand Until March 22, 2022

Sponsor: Agilent

Register free: ​https://www.biopharminternational.com/bp_w/elevating

Related to this article

View more
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more